Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: p.G12C-mutated pancreatic cancer are unknown. METHODS: p.G12C-mutated pancreatic cancer who had received at least one previous systemic therapy. The primary objective of phase 1 was to assess safety and to identify the recommended dose for phase 2. In phase 2, patients received sotorasib at a dose of 960 mg orally once daily. The primary end point for phase 2 was a centrally confirmed objective response (defined as a complete or partial response). Efficacy end points were assessed in the pooled population from both phases and included objective response, duration of response, time to objective response, disease control (defined as an objective response or stable disease), progression-free survival, and overall survival. Safety was also assessed. RESULTS: The pooled population from phases 1 and 2 consisted of 38 patients, all of whom had metastatic disease at enrollment and had previously received chemotherapy. At baseline, patients had received a median of 2 lines (range, 1 to 8) of therapy previously. All 38 patients received sotorasib in the trial. A total of 8 patients had a centrally confirmed objective response (21%; 95% confidence interval [CI], 10 to 37). The median progression-free survival was 4.0 months (95% CI, 2.8 to 5.6), and the median overall survival was 6.9 months (95% CI, 5.0 to 9.1). Treatment-related adverse events of any grade were reported in 16 patients (42%); 6 patients (16%) had grade 3 adverse events. No treatment-related adverse events were fatal or led to treatment discontinuation. CONCLUSIONS: p.G12C-mutated advanced pancreatic cancer who had received previous treatment. (Funded by Amgen and others; CodeBreaK 100 ClinicalTrials.gov number, NCT03600883.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The CodeBreaK100 (NCT03600883) clinical trial evaluated the safety and efficacy of sotorasib in advanced KRASG12C-mutant cancers, including 38 patients with metastatic, previously chemotherapy-treated PDAC. In these patients, a 21% objective response rate (ORR), a median progression-free survival (PFS) of 4.0 months, and a median overall survival (OS) of 6.9 months were observed (26).”
From Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer (2024) · cites this paper as [26]
In the citing paper
“For example, sotorasib, adagrasib, and divarasib monotherapies have demonstrated objective response rates ranging from 7.1% to 53.4% and median progression-free survival of 4.0-13.1 months, 13-20”
From Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer (2024) · cites this paper as [16]
In the citing paper
“In the first published clinical series of KRASG12C inhibitor monotherapy in advanced PDAC, responses occurred in a minority of patients (~21%) and were generally transient75.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [75]
In the citing paper
“Even with recent advances in this space, currently only inhibitors targeting a specific KRAS mutation (KRAS G12C) have been FDA-approved in NSCLC (2–5).”
From Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors (2024) · cites this paper as [5]
In the citing paper
“Although recently developed KRAS G12C inhibitors, 10 including sotorasib and adagrasib, have shown antitumor activity in patients with previously treated KRAS G12C-mutated cancer, the extent of the clinical benefit remains limited, and better therapies to target KRAS G12C remain a high priority.[11][12][13][14][15][16][17][18]”
From Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation (2023) · cites this paper as [15]
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824
Self-citationK-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer
Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J.-O., Hochhauser, D., Arnold, D., Oh, D.-Y., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903387 · Cited by 2,302
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes
Initiative, A. P. C. G., Biankin, A. V., Waddell, N., Kassahn, K. S., Gingras, M.-C., Muthuswamy, L. B., Johns, A. L., Miller, D. K., Wilson, P. J., Patch, A.-M., et al. (2012) · Nature · doi:10.1038/nature11547 · Cited by 2,058
Sotorasib for Lung Cancers with KRAS p.G12C Mutation
Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., Italiano, A., Schuler, M., Borghaei, H., Barlesi, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103695 · Cited by 1,849
Self-citationDoebele, R. C., Drilon, A., Paz-Ares, L., Siena, S., Shaw, A. T., Farago, A. F., Blakely, C. M., Seto, T., Cho, B. C., Tosi, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30691-6 · Cited by 1,790
Self-citation
Cited by
Items 501–579 of 579
Xiong, S., Luo, D., Zhong, M., Huang, C., Deng, M., He, H., Shan, J., Yuan, T., Liang, J., Fan, Y., et al. (2026) · Materials Advances · doi:10.1039/d6ma00423g
Abdelsamia, M., Li, Y., Eastwood, D., & Rabinowitz, I. (2026) · Future Oncology · doi:10.1080/14796694.2026.2699426
Du, F., Liu, D., Jiao, A., & Xu, L. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1761167
Chen, J. Y., Saghapour, E., Kurmachalam, N., Oishe, G., & Sembay, Z. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.09.737590
Pashinskaya, E., Khnykav, А. М., Sobolevskaya, I. S., Побяржин, В. В., Кужель, Д. К., Kravchenko, N. A., Pahom, Z. R., & Matveev, D. S. (2026) · Vestnik of Vitebsk State Medical University · doi:10.22263/2312-4156.2026.3.39
Research on GI Cancer (Hepato-Pancreato-Biliary (HPB) Cancers)
Zhang, S., Chavda, A., & 范骥 (2026) · Springer eBooks · doi:10.1007/978-3-032-19175-5_19
Kawczak, P., Kawczak, K., & Bączek, T. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15145521
Pathway-driven therapeutic stratification in pancreatic ductal adenocarcinoma
Chuluyán, E., Grasso, D., Pasqua, A. V., Remolins, C., de Lima, A. P., Matamoros, K., Guerrieri, D., Kohan, G., Gottardo, F., Ledesma, M. M., et al. (2026) · Translational Oncology · doi:10.1016/j.tranon.2026.102920
Yang, X., Tao, X., Qi, W., Luo, R., Lan, T., Xie, K., Cai, Y., Gao, F., Lv, Y., Liu, C., et al. (2026) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2026.101718
Arshinnikova Anna, S., Tararina Valeria, V., Zuban Polina, A., Leshcheva Elizaveta, A., Bogdanova Irena, V., Fishchenko Ekaterina, A., Nadaraia Mariam, S., Zeynalova Sabina, I., Gorodkova Maria, E., Kamurzoev Ismail, A., et al. (2026) · International Journal of Science and Research Archive · doi:10.30574/ijsra.2026.20.1.1495
Chinese expert consensus on precision testing and molecular diagnosis of pancreatic cancer (2025)
Cao, D., Wu, J., Cui, J., Chen, X., Zhou, J., Li, W., Sun, J., Yang, L., Cheng, K., Xu, H., et al. (2026) · British Journal of Cancer · doi:10.1038/s41416-026-03522-x
Ehsan, S., Chaudhary, A., Mishra, D., Maurya, S., & Singh, M. P. (2026) · Research Square · doi:10.21203/rs.3.rs-10494308/v1
Guzauskas, G., Picozzi, V., Guzman, J. F. N. D. R., & Wang, B. (2026) · Journal of Medical Economics · doi:10.1080/13696998.2026.2707046
Wu, J., Chen, J., Elkihel, A., Lan, W., Fraunhoffer, N. A., Zhu, D., Lian, B., Galanakou, C., Bian, Z., Liu, X., et al. (2026) · Advanced Science · doi:10.1002/advs.76840
Bahat, I., Pinkert, Y., Baumann, A., Arbely, E., Miller, A. K., & Papo, N. (2026) · Scientific Reports · doi:10.1038/s41598-026-65091-6
Rethinking PDAC: from immunological silence to therapeutic opportunity
Kali, S. K., Ramesh, R. P. G., Alam, A., Fernández-Cabezudo, M. J., Al-Awadhi, A. M., Kishore, U., & al-Ramadi, B. K. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1909191
Hackett, D., Kane, L. E., Prina‐Mello, A., & Maher, S. G. (2026) · BMC Medicine · doi:10.1186/s12916-026-05134-x
Batool, R., Julve, M., Sadiq, M. T., Rahman, S., Mansy, T., Mathiyalagan, N., Khan, S., Evans, J. S., Saleh, D., Karapanagiotou, E. M., et al. (2026) · Clinical Oncology · doi:10.1016/j.clon.2026.104323
Umino, R., Ishimoto-Namiki, U., Naito, C., Mizui, T., Miyata, A., Nara, S., Esaki, M., & Hiraoka, N. (2026) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-026-04675-z
Exploring ULK family in human cancer: insights into mechanisms and therapeutic potential
Li, M., Zhang, M., Wen, C., Cheng, H., Li, X., & Han, Y. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110352
Adjuvant Therapy in Pancreatic Ductal Adenocarcinoma—Past, Present, and Future
Tran, A., Jain, T., Fei, N. H., & Dudeja, V. (2026) · Cancers · doi:10.3390/cancers18172754
Meng, D., & Zhang, C. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1948028
Research advances in targeting claudin 18.2 in pancreatic ductal adenocarcinoma treatment
Wei, Y.-H., Zhang, S.-C., Guan, B., Jian, J.-N., Li, C.-G., Wang, Z.-K., Qu, H.-R., Li, Z., Liu, M.-Y., & Wang, J.-T. (2026) · World Journal of Gastroenterology · doi:10.3748/wjg.122906
Khan, H. Y., Hallak, M. N. A., Aboukameel, A., Bannoura, S. F., Uddin, M. H., Aboukameel, A., Alkan, F. K., Çağlayan, A. B., Alkan, H. K., Bao, B., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218804
Mariano, M. P., Sgarilli, E., Mijnlieff, D., Visuvasam, B., Blesio, A., Digiacomo, G., Cavazzoni, A., Ferracin, M., & Giovannetti, E. (2026) · Cancer Drug Resistance · doi:10.20517/cdr.2026.52 · Cited by 1
Orta, A., Hidalgo-León, M. Á., Lacalle-González, C., de Lope, M. M. R., Sanz-Criado, L., García-Foncillas, J., & Martínez-Useros, J. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1868595
RAS-targeted therapies for pancreatic cancer
Chan, L. L., Kwong, T. T., Yau, J., & Chan, S. L. (2026) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2026.100414
Mutant KRAS‐m 6 A Epitranscriptome Axis Promotes Colorectal Cancer and is a Therapeutic Target
Chen, D., Huang, P., Tao, R., Ji, F., Wei, Q., Ko, L. H., Zhou, L., Chen, H., Cheung, A. H. K., Kang, W., et al. (2026) · Advanced Science · doi:10.1002/advs.77627
Wang, E., Yao, A., Sasaki, M., Tanaka, R., Hassanein, M., Fujiwara, Y., & Tokuhara, T. (2026) · Journal of Clinical Question · doi:10.69854/jcq.2026.0026
The Landmark Series: Mutation-Based Therapy of Pancreatic Cancer
Schaefer, M. L., Tsai, S., & Blair, A. B. (2026) · Annals of Surgical Oncology · doi:10.1245/s10434-026-20366-0
The dawn of RAS-targeted therapy: a landmark breakthrough of daraxonrasib in pancreatic cancer
Liu, C., & Liu, L. (2026) · Clinical Cancer Bulletin · doi:10.1007/s44272-026-00072-4
Advances in KRAS-Targeted Therapies for Pancreatic Cancer
Peshin, S., Zahid, A., Takrori, E., Hamedi, Z., & Rahman, S. (2026) · Cancers · doi:10.3390/cancers18182961
Luo, H., Zhai, Z.-L., Xu, J., Li, X., Chen, Y.-W., & Bai, X. (2026) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.125300
Péczka, N., Keeley, A. B., Ábrányi‐Balogh, P., Orgován, Z., Petri, L., Grant, E. K., Quinn, C., Csanády, S., Ranđelović, I., Tóvári, J., et al. (2026) · Archiv der Pharmazie · doi:10.1002/ardp.70342
RAF1 scaffold integrity shapes chemogenetic degradation outcomes in KRAS-driven lung cancer models
Ovejero, L. D. L. P., Domostegui, A., García-Pérez, I. M., Aizpurua, G., Lomba-Riego, L., Ximénez‐Embún, P., Mayor‐Ruiz, C., Barbacid, M., & García‐Alonso, S. (2026) · Life Science Alliance · doi:10.26508/lsa.202603839
RAS/RAF/MAPK Alterations in Prostatic Adenocarcinoma: A Multi-Institutional Study
Chan, G. J., Zhu, X., Kwon, J. W., Tjota, M. Y., Wuori, D., Korentzelos, D. K., Mohebnasab, M., Greenland, N., Stohr, B. A., Simko, J., et al. (2026) · Human Pathology · doi:10.1016/j.humpath.2026.106270
Current landscape of RAS-targeted therapy for pancreatic cancer
Wu, Y. L., Herzberg, B., & Manji, G. A. (2026) · The Oncologist · doi:10.1093/oncolo/oyag379
Sun, Y., Pang, C., & Gao, J. (2026) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2026.01067
Muhammad, M., Khinji, A. A., Al-Ansari, M., Al-Marri, N., Al-Shaheen, S., & Malouche, D. (2026) · Cancers · doi:10.3390/cancers18193139
Harnessing novel agents to target KRAS-driven pathways in pancreatic cancer
Kreidi, J., Hoyek, C., Eslinger, C. R., & Bekaii-Saab, T. (2026) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2026.2738708
MTAP loss upregulates BCAT1 in pancreatic cancer and drives branched-chain amino acid dependency
Sheng, Y., Duan, L., Liu, Q., Zhang, Y., Chang, Y., Yan, J., Tan, H., Wang, Z., Xiao, Y., He, Y., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.118046
Hiyama, K., Nishigawa, M., Takagi, K., Sato, K., Hara, R. I., Furihata, K., Uchida, K., Wada, T., & Taniuchi, K. (2026) · Human Cell · doi:10.1007/s13577-026-01458-1
I macrofagi IL-1b+ alimentano l'infiammazione patogena nel tumore al pancreas
Vittoria, F. M. (n.d.) · Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele
Ebelt, N. D., Loganathan, S., Avsharian, L. C., Dąbrowska, K., Hansen, N. F., Pathak, K. V., Pirrotte, P., & Manuel, E. R. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.01.756059
Yamamoto, N., Dobersch, S., Robertson, T. M., Sim, J. H., Wallace-Povirk, A., Chew, N. W., Orellana, A. E., Aggrey-Fynn, J. E., Boila, L. D., Schutter, A., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.02.754697
Pancreatic Cancer KRAS Breakthrough: Drug Graveyard No More
Yu, P. Y., Oberstein, P. E., Maitra, A., & Hidalgo, M. M. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-4177 · Cited by 1
Targeting RAS in pancreatic cancer
Petrelli, F., Dottorini, L., & Zaniboni, A. (2026) · Cancer · doi:10.1002/cncr.70640 · Cited by 1
Beyond target presence: A cross-cancer contextual framework for siRNA therapeutics in solid tumors
Zhao, N., Zhang, Y., Qian, C., 张华巍, & Wang, L. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189732
Allosteric and covalent strategies for RAS-driven cancers from KRAS G12C to pan-RAS inhibition
Amran, N., & Rahman, H. (2026) · Integrative Biomedical Research · doi:10.25163/biomedical.10210959
Metastatic Pancreatic Cancer: Biology, Diagnosis, and Evolving Therapies
Rosowicz, A., & Javed, A. A. (2026) · Springer eBooks · doi:10.1007/978-3-032-28601-7_28
Zhao, W., Cheng, Z., Tian, K., Sun, M., Wang, Z., Jiao, M., Luebeck, J., Zhu, K., Zhang, X., Zuo, D., et al. (2026) · Advanced Science · doi:10.1002/advs.78200
Reframing cancer therapy through tumor plasticity
Shah, A. M., Marsh, B., & de Sauvage, F. J. (2026) · Nature Cancer · doi:10.1038/s43018-026-01232-0
Targeting (K)RAS in pancreatic ductal adenocarcinoma—ASCO 2026 highlights
Windhager, H., & Doleschal, B. (2026) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-026-01133-z
Tumor microenvironment-driven therapeutic resistance in pancreatic ductal adenocarcinoma
Li, H., Cui, J., Yang, X., Li, J.-H., Zhao, Q.-C., Li, C.-J., Fu, Q., Li, J.-Y., Zhou, Y., & Zhu, S.-K. (2026) · Cancer Drug Resistance · doi:10.20517/cdr.2026.102
Nickerson, J. L., Condon-Oldreive, S., Tsang, E. S., Zogopoulos, G., Ouellette, R. J., Haçarız, O., Antón-Pascual, B., Serrano, P. E., Gill, S., Vareki, S. M., et al. (2026) · Current Oncology · doi:10.3390/curroncol33100629
Meng, F., Fernandez, A., Luan, C., Attiyeh, M. A., Feng, Q., Lee, A., Feng, H., Li, T., Zhou, T., Li, Y., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.19.760262
Singh, S. (2026) · cIRcle (University of British Columbia) · doi:10.14288/1.0457030
Liu, Y., & Wang, M. (2026) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2026.10.003
Recent advances in scaffold-based KRAS G12C inhibitors: SAR and biological evaluation insights
Bhattacharjee, T., Kumar, A., Singh, T. G., & Bhatia, R. (2026) · RSC Medicinal Chemistry · doi:10.1039/d6md00337k
BindingDB (2026) · UC San Diego · doi:10.7270/q27p94b7
BindingDB (2026) · UC San Diego · doi:10.7270/q23201sz
Rethinking radiation therapy in the era of RAS inhibition for pancreatic cancer
Chuong, M. D., & O'Reilly, E. M. (2026) · The Oncologist · doi:10.1093/oncolo/oyag433
Fatima, F., Javed, M. A., Mirza, A., Ahmad, S., Shahzad, Z., & Murad, A. (2026) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000001387
Intrinsic resistance to KRAS inhibition: Interfering with interferon
Miguel‐López, B., & Drosten, M. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.10.001
Pancreatic cancer: The RAS paradigm shift
Soff, S. P., & O'Reilly, E. M. (2026) · PLoS Medicine · doi:10.1371/journal.pmed.1005283
KRAS in pancreatic cancer: from molecular biology to transformative therapeutics
Abdelhakeem, A. A. F., Ganatra, N., Gul, K., Saxena, H., Mohammed, N., Ashraf, A., Jones, J. C., Carr, R., Bekaii‐Saab, T., Borad, M. J., et al. (2026) · Journal of Hematology & Oncology · doi:10.1186/s13045-026-01863-x
Emerging Strategies for KRAS Inhibition in Cancer: From G12C to Pan-RAS and Beyond
Flynn, C. R., Matallanas, D., Kölch, W., Cowzer, D., & Duffy, A. G. (2026) · Journal of Molecular and Clinical Medicine · doi:10.31083/jmcm51252
Xie, H., Wang, G., 原志庆, Li, Y., & Liu, Y. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218931
Synergizing Against RAS: The Evolving Landscape of Targeted Combinations in Pancreatic Cancer
Ghosh, A. K., Jazieh, K., Xie, H., Parish, M. A., Babiker, H. M., Bekaii‐Saab, T., Goenka, A. H., Knutson, K. L., Pandey, A., Fernández-Zapico, M. E., et al. (2026) · Cancers · doi:10.3390/cancers18213519
Zhang, Z.-K., Yao, S.-B., Sun, H., Wang, C., & Huang, H.-J. (2026) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.124979
Alem, M., Msakem, M., Abbassi, M. B., Keita, D., Amaadour, L., Oualla, K., Benbrahim, Z., Arifi, S., & Mellas, N. (2026) · Journal of Medical and Radiation Oncology · doi:10.53011/jmro.2026.01.03
Shahiwala, A. (2026) · Cancer Investigation · doi:10.1080/07357907.2026.2754437
Ji-chuan, X., Wang, X., Dai, H.-C., Li, J., Nie, Y., Xu, F.-Q., Wu, Z.-J., & Huang, W. (2026) · World Journal of Gastroenterology · doi:10.3748/wjg.126038
The RAS revolution in gastrointestinal cancers: Where we are and where we go next
Cordani, M., Korc, M., & Li, M. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218963
Alsaikhan, F. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s646519
Chen, R., Fu, M., Lin, H., Jiang, Q., Li, C., Xu, L., Wu, R., Zhang, K., Chen, Y., & Wu, L. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1930284
Hur, J., George, S., Mukherjee, S., & Hatoum, H. A. (2026) · Cancers · doi:10.3390/cancers18223616
Av, K., Таразов, П. Г., & Lobachev, A. A. (2026) · Perm Medical Journal · doi:10.17816/pmj4355-16
Metadata
- Authors
- Strickler, J. H., Satake, H., George, T. J., Yaeger, R., Hollebecque, A., Garrido-Laguna, I., Schuler, M., Burns, T. F., Coveler, A. L., Falchook, G. S., Vincent, M., Sunakawa, Y., Dahan, L., Bajor, D., Rha, S.-Y., Lemech, C., Juric, D., Rehn, M., Ngarmchamnanrith, G., Jafarinasabian, P., Tran, Q., & Hong, D. S.
- Affiliations
- Kansai Medical University (JP)
- From Duke University Medical Center, Durham, NC (J.H.S.); Kansai Medical University, Shinmachi, Hirakata (H.S.), and St. Marianna University School of Medicine, Kawasaki (Y.S.) — both in Japan; University of Florida, Gainesville (T.J.G.); Memorial Sloan Kettering Cancer Center, New York (R.Y.); Gustave Roussy Cancer Center, Université Paris-Saclay, Villejuif (A.H.), and Marseille University Hospital, Marseille (L.D.) — both in France; Huntsman Cancer Institute, University of Utah, Salt Lake City (I.G.-L.); West German Cancer Center, University Hospital Essen, Essen (M.S.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (T.F.B.); Fred Hutchinson Cancer Center, University of Washington, Seattle (A.L.C.); Sarah Cannon Research Institute at HealthONE, Denver (G.S.F.); London Regional Cancer Program, London, ON, Canada (M.V.); University Hospitals Cleveland Medical Center, Cleveland (D.B.); Yonsei Cancer Center, Seoul, South Korea (S.-Y.R.); Scientia Clinical Research and Prince of Wa...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-01-05
- Volume
- 388
- Issue
- 1
- Pages
- 33-43
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC10506456
- OpenAlex
- W4312094134
- Semantic Scholar
- 488922b069e36918a499827187276c02b891cb58
- Cited by
- 527
- References
- 34
- Citations by year
- 2026: 138 · 2025: 169 · 2024: 142 · 2023: 78
- FWCI
- 40.70
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Funders
- Amgen Inc.
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- sotorasib, KRAS G12C mutation, advanced pancreatic cancer, KRAS inhibitors, metastatic pancreatic cancer, previously treated patients, objective response, progression-free survival, overall survival, treatment safety, adverse events
- MeSH terms
- Immune Checkpoint Inhibitors, Administration, Oral, Humans, Lung Neoplasms, Mutation, Pancreatic Neoplasms, Piperazines, Pyridines, Pyrimidines, Proto-Oncogene Proteins p21(ras), Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.